Killing time for cancer cells

被引：73

作者：

Klein, S

McCormick, F

Levitzki, A

机构：

[1] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA

[2] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signalling, IL-91904 Jerusalem, Israel

来源：

NATURE REVIEWS CANCER | 2005年 / 5卷 / 07期

关键词：

D O I：

10.1038/nrc1651

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As the signalling pathways that control cellular proliferation and death are unravelled, a range of targets have emerged as candidates for molecular cancer therapy. For their survival, cancer cells depend on a few highly activated signalling pathways; inhibition of these pathways has a strong apoptotic effect and can lead to tumour regression. But drugs that exploit this weakness, such as imatinib, have not cured patients: withdrawal of the drug leads to disease recurrence, and sustained treatment leads to the emergence of drug- resistant clones. Can cancer be cured, or will it have to be controlled as a chronic disease?

引用

收藏

页码：573 / 580

页数：9

相关论文

共 67 条

[51] Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment [J].

Roche-Lestienne, C ;

Preudhomme, C .

SEMINARS IN HEMATOLOGY, 2003, 40 (02) :80-82

[52] Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity [J].

Schimmer, AD ;

Welsh, K ;

Pinilla, C ;

Wang, ZL ;

Krajewska, M ;

Bonneau, MJ ;

Pedersen, IM ;

Kitada, S ;

Scott, FL ;

Bailly-Maitre, B ;

Glinsky, G ;

Scudiero, D ;

Sausville, E ;

Salvesen, G ;

Nefzi, A ;

Ostresh, JM ;

Houghten, RA ;

Reed, JC .

CANCER CELL, 2004, 5 (01) :25-35

[53] Reactivation of mutant p53: a new strategy for cancer therapy [J].

Selivanova, G ;

Kawasaki, T ;

Ryabchenko, L ;

Wiman, KG .

SEMINARS IN CANCER BIOLOGY, 1998, 8 (05) :369-378

[54] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

[55] Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol [J].

Shapiro, GI .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4270S-4275S

[56] Chronic myelogenous leukemia: mechanisms underlying disease progression [J].

Shet, AS ;

Jahagirdar, BN ;

Verfaillie, CM .

LEUKEMIA, 2002, 16 (08) :1402-1411

[57] Identification of human brain tumour initiating cells [J].

Singh, SK ;

Hawkins, C ;

Clarke, ID ;

Squire, JA ;

Bayani, J ;

Hide, T ;

Henkelman, RM ;

Cusimano, MD ;

Dirks, PB .

NATURE, 2004, 432 (7015) :396-401

[58] Apoptosis and melanoma chemoresistance [J].

Soengas, MS ;

Lowe, SW .

ONCOGENE, 2003, 22 (20) :3138-3151

[59] Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways [J].

Sordella, R ;

Bell, DW ;

Haber, DA ;

Settleman, J .

SCIENCE, 2004, 305 (5687) :1163-1167

[60]

Tsai CM, 1996, CANCER RES, V56, P1068

← 1 2 3 4 5 6 7 →